Bristol Myers Squibb Stock Gains 2.08% on $62.37 Close, EPS Forecast Falls 18.9%
Bristol Myers Squibb ended trading at $62.37, up 2.08% today and 12.56% month-to-date, outperforming the S&P 500 and medical sector. Q1 EPS is forecast at $1.46 (-18.9% yoy) on $10.86 billion revenue (-3%), with full-year EPS of $6.24 (+1.5%) and a forward P/E of 9.8 versus industry 20.16.
1. Stock Performance
Bristol Myers Squibb closed at $62.37, marking a 2.08% rise from the prior session and outperforming the S&P 500’s 0.43% loss. The stock’s 12.56% gain over the past month surpasses the medical sector’s 1.34% decline and the S&P 500’s 0.50% drop.
2. Q1 and Full-Year Forecasts
Analysts project Q1 EPS of $1.46, a 18.9% year-over-year decline, on revenue of $10.86 billion, down 3.0%. For the full year, EPS estimates stand at $6.24, a 1.5% increase, with sales of $47.02 billion, a 2.4% decrease versus last year.
3. Valuation Metrics
Bristol Myers Squibb trades at a forward P/E of 9.8, roughly half the 20.16 industry average. Its PEG ratio of 0.18 signals low valuation relative to expected growth, compared with a 1.54 average for the biomedical and genetics industry.